Literature DB >> 14759781

Magnetic resonance imaging in the preoperative evaluation of breast cancer: primum non nocere.

Monica Morrow.   

Abstract

Entities:  

Mesh：

Year:  2004        PMID： 14759781     DOI： 10.1016/j.jamcollsurg.2003.10.013

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN： 1072-7515            Impact factor:   6.113


× No keyword cloud information.
  6 in total

1.  Vacuum-assisted biopsies under MR guidance: results of 72 procedures.

Authors:  C Malhaire; C El Khoury; F Thibault; A Athanasiou; P Petrow; L Ollivier; A Tardivon
Journal:  Eur Radiol       Date:  2010-01-30       Impact factor: 5.315

2.  Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer.

Authors:  Filippo Montemurro; Laura Martincich; Giovanni De Rosa; Stefano Cirillo; Vincenzo Marra; Nicoletta Biglia; Marco Gatti; Piero Sismondi; Massimo Aglietta; Daniele Regge
Journal:  Eur Radiol       Date:  2005-01-27       Impact factor: 5.315

3.  An anthropomorphic phantom for quantitative evaluation of breast MRI.

Authors:  Melanie Freed; Jacco A de Zwart; Jennifer T Loud; Riham H El Khouli; Kyle J Myers; Mark H Greene; Jeff H Duyn; Aldo Badano
Journal:  Med Phys       Date:  2011-02       Impact factor: 4.071

4.  MR-guided vacuum-assisted breast biopsy in the management of incidental enhancing lesions detected by breast MR imaging.

Authors:  G Carbognin; V Girardi; A Brandalise; I Baglio; A Bucci; F Bonetti; R Pozzi Mucelli
Journal:  Radiol Med       Date:  2011-02-01       Impact factor: 3.469

Review 5.  The choice of the correct imaging modality in breast cancer management.

Authors:  Emilio Bombardieri; Luca Gianni
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-04       Impact factor: 9.236

6.  Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Authors:  Rita A Mukhtar; Christina Yau; Mark Rosen; Vickram J Tandon; Nola Hylton; Laura J Esserman
Journal:  Ann Surg Oncol       Date:  2013-06-19       Impact factor: 5.344
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.